Peli BioThermal wins at Asia-Pacific bioprocessing awards

Published: 18-Mar-2021
Regulatory

This is the third year running Peli Biothermal has won at the awards

Peli BioThermal has been announced winner of the Best Temperature Control Packaging Provider - Passive category at the annual Asia-Pacific Bioprocessing Excellence awards 2021.

The company reportedly won the award for its high-performing passive packaging serving the biopharma industry.

Benson Teo, Peli BioThermal’s Senior Director of Sales, Asia, said: “We are honoured and delighted to win this third award in succession is a fantastic achievement. It is amazing to win an award for our outstanding passive packaging products, repeating our previous success in 2019 when we also won this award category.

“As the company expands its presence in Asia we are excited to accept this latest award which recognises our ongoing commitment to delivering excellence and innovation to the biologics sector in Asia and the rest of the world.”

The award was presented virtually at the 5th annual edition of the ceremony on 17th March 2021, which was reportedly attended by more than 500 representatives from Asian biologistics businesses.

  • Companies:
  • Peli BioThermal
See more

You may also like

Regulatory

Peli BioThermal announces global brand unification

Read more
The change to the company’s brand name takes effect immediately and a website will launch in the coming weeks, with further brand changes throughout 2021

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. The rising importance of preservative efficacy testing When considering the regulation and validation of pharmaceutical products, the efficacy of the active pharmaceutical ingredient (API) is often the main concern
  5. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

Peli BioThermal announces global brand unification

The change to the company’s brand name takes effect immediately and a website will launch in the coming weeks, with further brand changes throughout 2021
Regulatory

How global air cargo trends are reshaping pharmaceutical transport

As we welcome the new decade and the exciting advances it’s expected to unleash, many of the forces that shaped the past decade for transporting pharmaceuticals will continue. Price pressures, alternatives to air freight and increasing automation are just a few. However, there are emerging trends that make 2020 unique
Packaging

Cool Logistics achieves laboratory accreditation success

A first for a leading manufacturer of temperature-controlled packaging solutions
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Subscribe now